Abstract
Immunotherapy with checkpoint inhibitors is changing the face of oncology treatments for many tumors, and endometrial carcinoma may not be an exception. Several endometrial cancer groups from the molecular taxonomy are characterized by having an ultramutated/hypermutated genome, which could be the first Achilles' heel identified in this malignancy in decades.
- Received August 17, 2016.
- Accepted September 1, 2016.
- Copyright {copyright, serif}2016, American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Published OnlineFirst October 3, 2016
doi: 10.1158/1078-0432.CCR-16-1820
Immunotherapy in endometrial cancer: In the nick of time.
Permalink:
Jump to section
Advertisement